How Tilray Brands Makes its Money: Revenue Breakdown

How Does Tilray Brands Make its Money?

Tilray Brands Competitors

Tilray Brands’s key competitors and comparable public companies in the cannabis sector include Constellation Brands, Anheuser Busch Inbev, Pfizer, and Coca-Cola. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Tilray Brands stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

Cannabis (Canadian Adult-Use & Medical) — 36% of Revenue

Canadian cannabis generated $250 million but declined 3.8%, reflecting the ongoing challenges of the oversupplied Canadian adult-use market. Tilray is the #1 cannabis company in Canada by market share (approximately 8–10% of the total market), selling dried flower, pre-rolls, edibles, extracts, and vapes under brands including Good Supply, RIFF, Broken Coast, and Tilray. The Canadian cannabis market has been brutal since legalization in 2018: oversupply from too many licensed producers, price compression from discount brands, an extensive illegal market that competes on price and convenience, and heavy excise taxes that squeeze margins.

Medical cannabis in Canada is a smaller but more stable business, with patients accessing cannabis through prescriptions with insurance reimbursement possibilities. Tilray’s medical division also supplies cannabis to patients in Israel, Australia, and other countries with medical cannabis programs. The overall decline reflects the maturation and competitive saturation of the Canadian recreational market, where hundreds of licensed producers compete for a market that has grown more slowly than initial projections. Tilray has maintained share through brand diversification (premium through Broken Coast, value through Good Supply) and operational efficiency, but growth in Canadian cannabis will likely remain flat to low-single-digit for the foreseeable future.

Cannabis (International) — 11% of Revenue

International cannabis revenue of $80 million, growing 23.1%, is the most promising cannabis segment, driven primarily by Germany — where Tilray holds the dominant position as the largest medical cannabis supplier. Germany legalized recreational cannabis in April 2024 through a club-based model, and while the initial regulatory framework is more restrictive than Canada’s (sales are limited to non-profit cannabis social clubs and personal cultivation), the broader trend toward German legalization creates a potential path to commercial retail sales. Tilray’s existing medical cannabis supply chain in Germany — including production facilities and a pharmaceutical distribution license — gives it a first-mover advantage that would be extremely difficult for competitors to replicate.

Beyond Germany, Tilray operates in 20+ international markets including Portugal, the UK, Poland, Australia, and New Zealand. The 23.1% growth reflects both expanded patient populations in existing markets and new market entries. International cannabis is the long-term growth thesis for Tilray: as European and other countries progressively legalize or expand medical cannabis programs, Tilray’s established supply chains and regulatory relationships position it to capture disproportionate market share.

Beverage Alcohol (Craft Beer, Spirits) — 36% of Revenue

Beverage alcohol revenue of $250 million, growing 8.7%, comes from Tilray’s portfolio of craft beer brands and spirits, including SweetWater Brewing (Atlanta, one of the top 15 craft breweries in the U.S.), Montauk Brewing (a premium Long Island brand), Alpine Beer (San Diego), Green Flash, and Breckenridge Distillery (Colorado bourbon and spirits). Tilray has been aggressively acquiring craft beverage brands since 2021, building what management describes as the 5th largest craft beer company in the United States.

This strategy serves a dual purpose: it generates stable, positive-cash-flow revenue today, and it builds a beverage distribution and brand infrastructure that could be rapidly repurposed for cannabis-infused beverages if U.S. federal legalization or rescheduling occurs. The thesis is that Tilray, with existing craft beer distribution relationships across thousands of retail accounts, would be uniquely positioned to distribute cannabis beverages through the same channels. The 8.7% growth is healthy for the craft beer category, which has faced headwinds from the broader shift toward spirits, hard seltzers, and non-alcoholic beverages.

Wellness (Hemp Foods, CBD) — 7% of Revenue

Wellness revenue of $50 million, flat year-over-year, comes primarily from Manitoba Harvest, the world’s largest hemp food company, selling hemp hearts, protein powders, and oils through major grocery retailers across the U.S. and Canada. This segment provides a small but steady revenue base and additional brand recognition. Growth has stalled as the initial CBD wellness boom has faded and the hemp food market has matured, but Manitoba Harvest maintains its dominant position in the hemp superfood category.

Tilray Brands (TLRY) Income Statement

All values in millions USD unless otherwise stated.

Financial data sourced from Tilray Brands SEC Filings.

Tilray Brands (TLRY) Key Financial Metrics

• Gross Margin: 35.7%
• Operating Margin: -14.3%
• Revenue Growth: 11.1%

Is Tilray Brands Profitable?

No, Tilray is not profitable, posting a $150 million net loss in 2024. However, this is a dramatic improvement from the $1.4 billion loss in 2023, which included massive goodwill impairment charges from the writedown of cannabis acquisitions made at peak valuations. The 35.7% gross margin is reasonable for a consumer products company, and operating losses narrowed from $190 million to $100 million as Tilray reduced overhead and rationalized operations. The -14.3% operating margin reflects the high fixed costs of cannabis cultivation and production facilities that are underutilized due to Canadian market conditions, plus continued investment in international market development.

Tilray generates positive adjusted EBITDA (approximately $50–80 million) when excluding non-cash charges, which management highlights as evidence of operational progress. The path to GAAP profitability requires sustained international cannabis growth, continued cost savings from operational restructuring, and ideally, a U.S. legalization event that would unlock the beverage alcohol distribution network for cannabis products. The company held approximately $300 million in cash and maintains a manageable debt profile relative to cannabis peers.

Tilray Brands (TLRY): What to Watch

1. U.S. federal cannabis legalization or rescheduling — the single biggest binary catalyst; Tilray’s craft beer distribution network and brand portfolio would gain enormous value overnight if cannabis beverages could be sold through existing alcohol distribution channels; however, the timeline for federal action remains uncertain
2. German recreational cannabis market evolution — Germany is the largest potential cannabis market in Europe; any move from the current club-based model toward commercial retail sales would dramatically expand Tilray’s addressable market in a country where it already holds the dominant supply position
3. Operating margin improvement and positive free cash flow — narrowing losses are encouraging, but Tilray needs to demonstrate sustained GAAP profit improvement; achieving positive operating income on the current revenue base would validate the diversification strategy
4. Craft beer market share and acquisition strategy — Tilray’s goal of becoming a top-5 U.S. craft brewer depends on both organic growth and further M&A; the craft beer market is highly fragmented with thousands of small breweries, providing ongoing acquisition targets, but integration and brand management of diverse regional brands is operationally complex
5. Canadian cannabis market stabilization — as the weakest licensed producers exit the market (through bankruptcy or acquisition) and the illegal market shrinks, Tilray’s dominant Canadian market share should translate into better pricing power and margin improvement over time

Tilray Brands (TLRY) Financial Summary

Tilray Brands is the largest cannabis company outside of the U.S. by revenue, but its investment thesis depends more on the future than the present. The $700 million in revenue and 35.7% gross margin demonstrate a viable multi-category consumer products business spanning cannabis, craft beer, and wellness, but the $150 million net loss and -14.3% operating margin show that current operations alone don’t justify the valuation. The strategic logic — building cannabis, beer, and wellness distribution in parallel so that U.S. legalization triggers a rapid synergy — is sound in theory but depends on a political event whose timing is impossible to predict. Germany and international cannabis provide a more concrete near-term growth vector, while Canadian cannabis is mature and oversupplied. At $1.5 billion in market cap, Tilray is priced as an option on U.S. cannabis legalization with a beer company as the premium — investors should evaluate whether the operational improvements and international growth are sufficient to sustain the stock even without the legalization catalyst.